| Literature DB >> 34307908 |
Akifumi Kuwano1,2, Masatake Tanaka1, Hideo Suzuki1, Miho Kurokawa1, Koji Imoto1, Shigeki Tashiro1, Takeshi Goya1, Motoyuki Kohjima1, Masaki Kato1, Yoshihiro Ogawa1,3.
Abstract
Liver fibrosis induces intrahepatic microcirculation disorder and hypoxic stress. Hypoxic stress has the potential for an increase in the possibility of more liver fibrosis and carcinogenesis. Liver biopsy is a standard method that evaluates of intrahepatic hypoxia, however, is invasive and has a risk of bleeding as a complication. Here, we investigated the hypoxia reactive gene expressions in peripheral blood mononuclear cells (PBMC) from chronic liver disease patients to evaluate intrahepatic hypoxia in a non-invasive manner. The subjects enrolled for this study were composed of 20 healthy volunteers (HV) and 48 patients with chronic liver disease (CLD). CLD patients contained 24 patients with chronic hepatitis(CH)and 24 patients with liver cirrhosis (LC). PBMC were isolated from heparinized peripheral blood samples. We measured the transcriptional expression of hypoxia reactive genes and inflammatory cytokines by quantitative RT-PCR. mRNA expression of adrenomedullin (AM), vascular endothelial growth factor A (VEGFA) superoxide dismutase (SOD), glutathione peroxidase (GPx) (p < 0.05), Interleukin-6 (IL-6), transforming growth factor-beta (TGF-β) and heme oxygenase-1 (HO-1) in CLD group were significantly higher than HV. AM mRNA expression is correlated with serum lactate dehydrogenase (LDH), serum albumin (Alb), IL6, and SOD mRNA expression. The hypoxia reactive gene expression in PBMCs from CLD patients was more upregulated than HV. Especially, angiogenic genes were notably upregulated and correlated with liver fibrosis. Here, we suggest that mRNA expression of AM in PBMCs could be the biomarker of intrahepatic hypoxia.Entities:
Keywords: AM, Adrenomedullin; ANGPTL4, Angiopoietin-like 4; Adrenomedullin; CH, chronic hepatitis; CLD, chronic liver disease; Chronic liver disease; GPx, glutathione peroxidase; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIF, hypoxia inducible factor; HO-1, heme oxygenase -1; HV, healthy volunteers; IL-6, Interleukin-6; Intrahepatic hypoxia; LC, liver cirrhosis; LDH, lactate dehydrogenase; MCP-1, Monocyte chemoattractant protein-1; PBMC, Peripheral blood mononuclear cells; PT, prothrombin time; Peripheral blood mononuclear cells; ROS, reactive oxygen species; SOD, Superoxide dismutase; TGF-β, transforming growth factor-beta; TNF-α, Tumor Necrosis Factor-α; VEGF, vascular endothelial growth factor; VEGFA, vascular endothelial growth factor A; VEGFR2, vascular endothelial growth factor receptor 2
Year: 2021 PMID: 34307908 PMCID: PMC8283323 DOI: 10.1016/j.bbrep.2021.101068
Source DB: PubMed Journal: Biochem Biophys Rep ISSN: 2405-5808
Clinical characteristics of the patients.
| HV | CLD | p value | CH | LC | p value | |
|---|---|---|---|---|---|---|
| Number | 20 | 48 | 24 | 24 | ||
| Age(years) | 35 (33.25–48.25) | 63 (56–71) | 62 (55.75–67.25) | 68 (59.5–76.5) | ||
| Gender(M/F) | 13/7 | 28/20 | 10/14 | 18/6 | ||
| Etiology (HCV/HBV/NASH/others) | 25/11/5/7 | 7/8/4/4 | 18/3/1/3 | |||
| With HCC | 0 | 13 | 0 | 13 | ||
| T.Bil(mg/dl) | 0.9 (0.8–1.1) | 0.7 (0.5–1.0) | 0.6 (0.4–1.0) | 0.7 (0.5–1.25) | ||
| ALT(IU/l) | 19 (11.5–40) | 23 (14.25–48) | 23 (12.75–30) | 43 (17–48.5) | ||
| LDH(IU/l) | 191 (118–219) | 205 (178.75–236.5) | 187.5 (127.5–215) | 218 (186.5–247.5) | ||
| T.chol(mg/dl) | 192 (150–214) | 168 (149–194) | 181 (157–212) | 159 (125.5–177.5) | ||
| Albumin(g/dl) | 4.7 (4.4–4.8) | 4.05 (3.33–4.28) | 4.15 (3.88–4.35) | 3.7 (3.2–4.05) | ||
| Platelet count(X104/μl) | 22.95 (21.93–26.23) | 12.4 (9.68–17.15) | 17.1 (14.58–21.83) | 10.5 (7.05–12.3) | ||
| FIB4 index | 1.27 (0.72–1.88) | 4.09 (2.02–6.46) | 1.99 (1.49–3.12) | 5.53 (4.77–7.57) |
Primer sequences.
| Gene | Primer sequences(5'~3′) |
|---|---|
| GAPDH | F:ATCACCATCTTCCAGGAGCGA |
| R:TTCTCCATGGTGGTGAAGACG | |
| AM | F:AGTCGTGGGAAGAGGGAACT |
| R:CCCTGGAAGTTGTTCATGCT | |
| VEGFA | F:CCTTGCTGCTCTACCTCCAC |
| R:CACACAGGATGGCTTGAAGA | |
| ANGPTL4 | F:CACCATGAGCGGTGCTCCGACGGC |
| R:GGAGGCTGCCTCTGCTGCCA | |
| Tie2 | F:TACTAATGAAGAAATGACCCTGG |
| R:GGAGTGTGTAATGTTGGAAATCT | |
| HIF-1α | F:ACCATGCCCCAGATTCAGGA |
| R:ATCAGTGGTGGCAGTGGTAGTGGT | |
| HO-1 | F:ATG ACA CCA AGG ACC AGA GC |
| R:GTG TAA GGA CCC ATC GGA GA | |
| VEGFR2 | F:GTGACCAACATGGAGTCGTG |
| R:TGCTTCACAGAAGACCATGC | |
| SOD | F:AGGGCATCATCAATTTCGAG |
| R:ACATTGCCCAAGTCTCCAAC | |
| Catalase | F:CTGGAGAAGTGCGGAGATTC |
| R:AGTCAGGGTGGACCTCAGTG | |
| GPx | F:GTAGTGCTGGACAGTGACAACC |
| R:ATATTTGGAGGCAGTGGGAGATG | |
| IL-6 | F:GACAGCCACTCACCTCTTCA |
| R:TTCACCAGGCAAGTCCCTC | |
| TGF-β | F:TGAACCGCCTTTCCTGCTTCTCATG |
| R:GCGGAAGTCAATGTACAGCTGCCGC | |
| TNF-α | F:CCCAGGCAGTCAGATCATCTT |
| R:TCTCAGCTCCACGCCATT | |
| MCP-1 | F:GACAAGCAAACCCAAACTCC |
| R:GCAATTTCCCCAAGTCTCTG |
AM, Adrenomedullin; VEGFA, Vascular endothelial growth factor A; ANGPTL4, Angiopoietin-like 4; HIF-1α, Hypoxia inducible factor 1α; HO-1, Heme oxygenase -1; VEGFR2, vascular endothelial growth factor receptor 2; SOD, Superoxide dismutase; GPx, glutathione peroxidase; IL-6, Interleukin-6; TGF-β, transforming growth factor beta; TNF-α, Tumor Necrosis Factor-α; MCP-1, Monocyte chemoattractant protein-1.
Fig. 1mRNA expression levels of AM, VEGFA, ANGPTL4, Tie2, HIF-1α、HO-1 and VEGFR2 genes in CLD and HV (A). RT-PCR analyses of the expression levels of AM gene in HV, CH and LC (B). RT-PCR analyses of the expression levels of VEGFA gene in HV, CH and LC (C). *p < 0.05 compared with HV, **p < 0.01 compared with HV, ♯ p < 0.05 compared with CH and ♯♯ p < 0.01 compared with CH.
HV, healthy volunteers; CH, chronic hepatitis; LC, liver cirrhosis; AM, Adrenomedullin; VEGFA, Vascular endothelial growth factor A; ANGPTL4, Angiopoietin-like 4; HIF-1α, Hypoxia inducible factor 1α; HO-1, Heme oxygenase -1; VEGFR2, vascular endothelial growth factor receptor 2.
Fig. 2mRNA expression levels of SOD, Catalase and GPx genes in CLD and HV (A). RT-PCR analyses of the expression levels of SOD gene in HV, CH and LC (B). *p < 0.05 compared with HV, **p < 0.01 compared with HV, ♯ p < 0.05 compared with CH and ♯♯ p < 0.01 compared with CH·
HV, healthy volunteers; CH, chronic hepatitis; LC, liver cirrhosis; SOD, Superoxide dismutase; GPx, glutathione peroxidase.
Fig. 3mRNA expression levels of IL-6, TNF-β, TNFα and MCP-1 genes in CLD and HV(A). RT-PCR analyses of the expression levels of IL-6 gene in HV, CH and LC (B). *p < 0.05 compared with HV, **p < 0.01 compared with HV, ♯ p < 0.05 compared with CH and ♯♯ p < 0.01 compared with CH·
HV, healthy volunteers; CH, chronic hepatitis; LC, liver cirrhosis; IL-6, Interleukin-6; TGF-β, transforming growth factor beta; TNF-α, Tumor Necrosis Factor-α; MCP-1, Monocyte chemoattractant protein-1.
Fig. 4Correlations between AM mRNA expression and other parameters; serum LDH (A), serum Alb (B), IL-6 mRNA expression (C) and SOD mRNA expression (D).AM, Adrenomedullin; LDH, lactate dehydrogenase; Alb, Albumin; IL-6, Interleukin-6; SOD, Superoxide dismutase.